ANNX Projected Dividend Yield
Annexon Inc ( NASDAQ : ANNX )Annexon, Inc. is a clinical-stage biopharmaceutical company. Co. is engaged in advancing a late-stage clinical platform of therapies for people living with classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. Using its platform, it is identifying and characterizing the role of the complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology. Its lead candidate, ANX005, is an investigational monoclonal antibody (mAb), formulated for intravenous administration in a pivotal Phase III clinical trial for the treatment of patients with Guillain-Barre Syndrome (GBS). 21 YEAR PERFORMANCE RESULTS |
ANNX Dividend History Detail ANNX Dividend News ANNX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |